Your session is about to expire
← Back to Search
Histamine H3 Receptor Antagonist
Pitolisant (Wakix) for Restless Legs Syndrome
Phase 4
Recruiting
Research Sponsored by William Ondo, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week, 2 weeks, 4 weeks, 8 weeks, 11 weeks, 16 weeks, and 17 weeks
Awards & highlights
Summary
This trial is testing Pitolisant, a medication that may help improve symptoms of Restless Legs Syndrome (RLS). It targets patients who haven't found relief with standard treatments. The drug works by balancing brain chemicals that affect wakefulness and alertness.
Eligible Conditions
- Restless Legs Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 week, 2 weeks, 4 weeks, 8 weeks, 11 weeks, 16 weeks, and 17 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week, 2 weeks, 4 weeks, 8 weeks, 11 weeks, 16 weeks, and 17 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
International RLS Rating Scale (IRLS)
Secondary outcome measures
Clinical Global Impressions - Change
Epworth Sleepiness Scale (ESS)
Fatigue Severity Scale (FSS)
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Pitolisant (Wakix)Experimental Treatment1 Intervention
Pitolisant will be titrated weekly until maximum dosage of 35.6 mg. Titration is dependent on subjects response.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pitolisant
2016
Completed Phase 3
~400
Find a Location
Who is running the clinical trial?
William Ondo, MDLead Sponsor
4 Previous Clinical Trials
63 Total Patients Enrolled
2 Trials studying Restless Legs Syndrome
26 Patients Enrolled for Restless Legs Syndrome
Harmony Biosciences, LLCIndustry Sponsor
7 Previous Clinical Trials
1,900 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger